Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quanterix Corp (QTRX)

Quanterix Corp (QTRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 279,332
  • Shares Outstanding, K 46,711
  • Annual Sales, $ 137,420 K
  • Annual Income, $ -38,530 K
  • EBIT $ -115 M
  • EBITDA $ -108 M
  • 60-Month Beta 1.09
  • Price/Sales 1.85
  • Price/Cash Flow N/A
  • Price/Book 0.90

Options Overview Details

View History
  • Implied Volatility 160.50% (-69.34%)
  • Historical Volatility 91.43%
  • IV Percentile 76%
  • IV Rank 35.30%
  • IV High 355.53% on 11/11/25
  • IV Low 54.07% on 02/14/25
  • Expected Move (DTE 7) 1.06 (18.04%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 51
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,538
  • Open Int (30-Day) 3,416
  • Expected Range 4.83 to 6.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.53 +6.51%
on 02/12/26
8.15 -27.69%
on 01/16/26
-1.47 (-19.97%)
since 01/12/26
3-Month
5.08 +15.94%
on 11/13/25
8.77 -32.84%
on 01/09/26
+0.67 (+12.84%)
since 11/12/25
52-Week
4.05 +45.43%
on 05/14/25
8.77 -32.84%
on 01/09/26
-1.92 (-24.58%)
since 02/12/25

Most Recent Stories

More News
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection

Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix’s LucentAD® Complete LDT

QTRX : 5.89 (-1.51%)
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling

Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior...

QTRX : 5.89 (-1.51%)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that...

QTRX : 5.89 (-1.51%)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025

DGX : 206.86 (-1.18%)
EXAS : 103.23 (-0.19%)
ILMN : 114.44 (-1.67%)
ARVN : 11.84 (-9.59%)
PFE : 27.47 (-0.94%)
QTRX : 5.89 (-1.51%)
Quanterix Announces Landmark Nature Study Redefining Alzheimer’s Disease Neuropathology Prevalence

Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility

QTRX : 5.89 (-1.51%)
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director

IDYA : 31.52 (-1.19%)
TROW : 93.16 (-0.67%)
EXAS : 103.23 (-0.19%)
ILMN : 114.44 (-1.67%)
TMO : 509.82 (-3.29%)
SERA : 2.60 (+0.39%)
IR : 94.21 (-2.63%)
MTD : 1,357.92 (-2.49%)
QTRX : 5.89 (-1.51%)
LIFE : 10.25 (-0.58%)
Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

Publication in the journal ‘Brain’ confirms complementary roles of the biomarkers for predicting relapse and chronic disability progression in multiple sclerosis (MS) ...

QTRX : 5.89 (-1.51%)
Quanterix Releases Financial Results for the Third Quarter of 2025

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financial results for the...

QTRX : 5.89 (-1.51%)
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, November...

QTRX : 5.89 (-1.51%)
Quanterix Approves Key Governance Changes at Annual Meeting

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Quanterix...

QTRX : 5.89 (-1.51%)

Business Summary

Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa...

See More

Key Turning Points

3rd Resistance Point 6.80
2nd Resistance Point 6.48
1st Resistance Point 6.18
Last Price 5.89
1st Support Level 5.56
2nd Support Level 5.24
3rd Support Level 4.94

See More

52-Week High 8.77
Fibonacci 61.8% 6.97
Fibonacci 50% 6.41
Last Price 5.89
Fibonacci 38.2% 5.85
52-Week Low 4.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar